Article

Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome

Vanderbilt University, Нашвилл, Michigan, United States
Genetics in Medicine (Impact Factor: 6.44). 03/2005; 7(2):143-6. DOI: 10.1097/01.GIM.0000154299.22120.6A
Source: PubMed

ABSTRACT Hurler syndrome is a debilitating genetic disease with a typical life span of 5 to 8 years. Early hematopoietic stem cell transplantation (HSCT) mitigates disease symptoms and improves survival. However, morbidity and mortality associated with HSCT can limit its success. We describe the initial experience with combined use of enzyme replacement therapy (ERT, laronidase) and HSCT in Hurler syndrome.
Thirteen transplants were performed in 12 patients. ERT was given at a standard dose of 0.58 mg/kg per week. Transplant conditioning regimen and donor graft source were determined by institutional protocol.
The median age at initiation of ERT was 12 months (range, 8 to 18 months). The median duration of pre-HSCT ERT was 12 weeks (range, 4 to 28). All but 1 patient tested showed decrease in urinary GAG excretion during ERT. ERT infusion-related toxicity was limited to mild reactions. Development of antibodies to laronidase did not correlate with infusion reactions or responses in urinary GAG excretion. ERT was given for a median of 7 weeks (range, 3 to 20) after HSCT. After transplantation, eight patients demonstrated complete donor engraftment and four suffered graft failure. Two patients required ventilator support and three developed acute GVHD. Eleven of the 12 patients are surviving with a median follow-up of 3 months (range, 1 to 7 months).
In children with Hurler syndrome, ERT with HSCT is feasible and well tolerated. Development of antibodies against exogenous enzyme does not appear to correlate with infusion reactions or response to ERT. A prospective study is needed to determine the effect of concomitant ERT on transplant outcomes.

Download full-text

Full-text

Available from: Maged I Gharib, Jul 25, 2014
0 Followers
 · 
143 Views
  • Source
    • "Eight patients had complete donor engraftment and 11 of 12 survived at a median time of follow-up of 3 months (1 child died of pulmonary hemorrhage). Based on these case studies, it was concluded that the ERT and HCT combination therapy is safe and feasible, but prospective studies were needed to further evaluate the outcomes of co-modality therapy (Grewal et al 2005). The European study lead by Cox-Brinkman et al (2006) also observed that ERT with HCT has been well tolerated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: More than 500 patients with mucopolysaccharidosis type IH (MPS IH; Hurler syndrome) have been treated with hematopoietic cell transplantation (HCT) throughout the world since the introduction of transplantation as therapy almost 30 years ago. More recently, the availability of recombinant alpha-L-iduronidase (IDUA) has resulted in the widespread treatment of less severe forms of MPS I with enzyme replacement therapy (ERT). In addition, over 50 MPS IH patients have been treated with a combination of ERT and HCT. The rationale for both ERT and HCT stems from the pivotal experiments performed 4 decades ago that showed alpha-L-iduronidase supplied in the environment can correct the accumulation of substrate in MPS I cells. Our purpose is to address the multiple applications associated with the therapeutic delivery of IDUA: intermittent delivery of recombinant protein (ERT), continuous administration through cellular therapy (HCT), the use of other stem cells or, potentially, correction of the enzyme defect itself through gene therapy approaches. Even though gene therapy and non-hematopoietic stem cell approaches, have yet to be tested in a clinical setting, it is possible that all these approaches will in the near future be a part of a paradigm shift from unimodal to multimodal therapy for MPS I.
    Targets & therapy 01/2009; 2(4):743-51.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The different types (I–VII) of mucopolysaccharidoses (MPS), a hereditary lysosomal storage disorder where the enzyme defect leads to glycosaminoglycan deposits in different tissues, present with characteristic lesions of the central nervous system (CNS). This review reports the CT and MRI findings of patients suffering from mucopolysaccharidosis in the context with aspects of biochemistry, pathophysiology, histological findings and clinical course. Neuroradiological findings include hydrocephalus, focal or global brain atrophy, and spinal cord compression at the atlantoaxial joint. Cribriform white matter lesions, corresponding to mucopolysaccharide deposition in the enlarged perivascular space, combined with leukencephalopathy are found in about half of the patients. Another half of the patients show minor to severe myelopathy at the atlantoaxial joint due to cervical cord compression. These findings are observed mainly in patients with MPS type IV, but as well in nearly all patients with MPS type VI. In the literature brain involvement is described exclusively in MPS type I, II and III, but the authors show definite demyelination and widening of the perivascular space in a number of patients with MPS type VI, who additionally suffered from progressive visual deficits, caused by ocular and/or optic nerve involvement. Die verschiedenen Formen der Mukopolysaccharidosen (MPS), einer hereditären, lysosomalen Speicherkrankheit, die, bedingt durch einen Enzymdefekt, zu Glykosaminoglykanablagerungen in verschiedenen Geweben führt, weisen charakteristische Veränderungen des zentralen Nervensystems (ZNS) aus. In dieser Übersichtsarbeit werden die CT- und MRT-Befunde von Patienten mit Mukopolysaccharidosen in Zusammenhang mit biochemischen, pathophysiologischen und pathohistologischen Befunden sowie charakteristischen klinischen Symptomen und im Verlauf vorgestellt. Die neuroradiologischen Befunde des ZNS weisen neben einem Hydrozephalus, einer fokalen und/oder globalen Atrophie auch eine medulläre Kompression am kraniozervikalen Übergang auf. Hinzu kommen erweiterte perivaskuläre Räume und Veränderungen der weißen Substanz. In jeweils etwa der Hälfte aller Patienten werden diese sog. cribriformen Läsionen (bedingt durch perivaskuläre Mukopolysaccharidablagerungen) und eine Leukenzephalopathie sowie eine hohe zervikale Myelonkompression mit unterschiedlich ausgeprägter Myelomalazie gefunden. Diese Befunde sind in erster Linie bei Patienten mit MPS IV, aber auch in der Mehrzahl der Patienten mit MPS VI zu finden. In der Literatur wird angegeben, dass eine ZNS-Beteiligung lediglich bei Patienten mit MPS I, II und III zu finden ist, die Autoren haben jedoch Demyelinisierung und erweiterte perivaskuläre Räume auch bei Patienten mit MPS VI nachgewiesen, die zusätzlich auch an progredienter Visusminderung litten, bedingt durch eine Beteiligung der Kornea und/oder des Nervus opticus.
    Clinical Neuroradiology 09/2007; 17(3):141-158. DOI:10.1007/s00062-007-7017-1 · 1.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In many ways, the role of the genetic counselor working with patients and families with a lysosomal storage disease is similar to a counselor in other pediatric and adult counseling situations. The goals of counseling; education, access to health care, and supportive counseling are the same. Although the goals of counseling are simply stated, an effective counseling session is always a complex interaction. It is an empathic exchange where the counselor promotes understanding of the particular disease, the inheritance pattern, takes a family history, provides recurrence risks, and reviews diagnostic testing, disease management issues, and supportive resources, while simultaneously learning about family structure, dynamics, and the impact of the diagnosis. The counselor assesses the level of understanding about the disease and the appropriate resources to assist the patient and family facing an inherited disease. A balance of teaching and counseling and the ability to be flexible and responsive to the counselee is key for achieving an effective interaction. The chapter is designed as a resource for counselors or other health care providers interested in an update on counseling issues for this group of treatable lysosomal storage diseases. Six genetic counselors who have been involved with the lysosomal storage disease community for the last decade draw on their counseling expertise to provide a disease summary and clinical counseling pearls for Gaucher disease, Fabry disease, Mucopolysaccharidosis (MPS) type 1, MPS II, MPS VI, and Pompe disease.
    01/1970: pages 179-195;
Show more